Inactive

The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price modification to Sanofi Pasteur (Sanofi). Sanofi was awarded contract 75D30121D10576 in response to ... The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price modification to Sanofi Pasteur (Sanofi). Sanofi was awarded contract 75D30121D10576 in response to a competitive solicitation for the Vaccines for Children program. The CDC has determined that adding doses of the Dengue Vaccine (Dengvaxia) will be beneficial. The National Center for Immunization and Respiratory Diseases (NCIRD) awarded multiple indefinite delivery, indefinite quantity (IDIQ) contracts for the purchase of standard commercial pediatric vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA). The vaccines awarded under these contracts will be purchased for NCIRD’s immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and Section 13631of the Omnibus Budget Reconciliation Act of 1993. Awardees may also purchase these vaccines using their own state funds. Vaccines will be ordered through the NCIRD electronic vaccine ordering system. The initial contracts, awarded in April 2021 were established to support public sector ACIP recommended routine vaccinations for children. Contract 75D30121D10576 will be modified to support purchase of Dengue vaccine (Dengvaxia) for children in light of the ACIP approval and accompanying VFC resolution on June 24, 2021. On June 24, 2021, the Advisory Committee for Immunization Practices (ACIP) recommended all children 9 - 16 years of age residing in endemic jurisdictions who test sero-positive should receive the 3 dose regimen of Dengue vaccine. The accompanying VFC resolution was approved during the same meeting. Section 13631of the Omnibus Budget Reconciliation Act of 1993 requires children receive all recommended ACIP vaccines that have been approved via resolution by the VFC program. Sanofi is the only contractor that can meet HHS/CDC/NCIRD’s needs because there is only one manufacturer with an FDA-approved license for Dengue vaccine at this time—Sanofi Pasteur. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1 and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within ten (10) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Christina McMichael at wpn6@cdc.gov by July 17, 2021 at 4:00 PM EST.